Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tc 99m besilesomab - IBA

Drug Profile

Tc 99m besilesomab - IBA

Alternative Names: 99Tcm-BW250-183; BW 250 183; Scintimun; Tc 99m-labeled monoclonal antibody BW 250/183; Technetium-99m-antigranulocyte antibody BW 250-183; TLX66-CDx

Latest Information Update: 12 Jun 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CIS bio international
  • Class Monoclonal antibodies; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bone metastases; Infections; Inflammation; Osteomyelitis

Most Recent Events

  • 12 Jun 2015 Launched for Osteomyelitis (Diagnosis) in Austria, Belgium, Croatia, Finland, Germany, Latvia, Italy, Lithuania, Malta, Slovenia and Slovakia (IV) before June 2015
  • 23 Oct 2009 The Committee for Medicinal Products for Human Use recommends approval of Tc 99m besilesomab for Osteomyelitis diagnosis in the EU
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top